Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Avadel Pharmaceuticals ( (AVDL) ) has issued an announcement.
On November 18, 2025, Avadel Pharmaceuticals and Alkermes plc amended their original transaction agreement, increasing the cash consideration for Avadel’s shares from $18.50 to $21.00 per share, with the contingent value right remaining unchanged. This amendment followed an unsolicited proposal from H. Lundbeck A/S, which was initially considered superior by Avadel’s board. However, after reviewing both offers, Avadel’s board determined that Alkermes’ revised terms were more favorable, particularly the terms of the contingent value right. The acquisition, valuing Avadel at up to $2.37 billion, is expected to close in the first quarter of 2026, pending conditions and regulatory approvals.
The most recent analyst rating on (AVDL) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals’ stock score is primarily driven by strong financial performance improvements and positive earnings call sentiment. However, the stock’s valuation is a significant concern due to negative earnings and lack of dividends. Technical indicators show bullish momentum, but overbought conditions suggest caution. Overall, the stock presents a mixed outlook with potential for growth if profitability improves.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals plc is a biopharmaceutical company that focuses on transforming medicines to improve patients’ lives. The company develops innovative medications to address challenges faced by patients with current treatment options. Avadel’s commercial product, LUMRYZ™, is the first and only once-at-bedtime oxybate for extended-release oral suspension approved by the FDA for treating cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy.
Average Trading Volume: 2,704,798
Technical Sentiment Signal: Buy
Current Market Cap: $2.25B
For detailed information about AVDL stock, go to TipRanks’ Stock Analysis page.